Paul Telesca
Guest
Paul Telesca
Guest
Everyone that’s left for greener pastures has failed miserably. Intercept didn’t get NASH drug approved. Lundbeck, Migraine drug is a bust. Now, Biogen’s Alzheimer’s drug will likely get a no from FDA. For all its faults, Mitsubishi is still here paying the bills.